Literature DB >> 29895694

Cancer-mutation network and the number and specificity of driver mutations.

Jaime Iranzo1, Iñigo Martincorena2, Eugene V Koonin1.   

Abstract

Cancer genomics has produced extensive information on cancer-associated genes, but the number and specificity of cancer-driver mutations remains a matter of debate. We constructed a bipartite network in which 7,665 tumors from 30 cancer types are connected via shared mutations in 198 previously identified cancer genes. We show that about 27% of the tumors can be assigned to statistically supported modules, most of which encompass one or two cancer types. The rest of the tumors belong to a diffuse network component suggesting lower gene specificity of driver mutations. Linear regression of the mutational loads in cancer genes was used to estimate the number of drivers required for the onset of different cancers. The mean number of drivers in known cancer genes is approximately two, with a range of one to five. Cancers that are associated with modules had more drivers than those from the diffuse network component, suggesting that unidentified and/or interchangeable drivers exist in the latter.

Entities:  

Keywords:  bipartite networks; cancer types; community detection; driver mutations; passenger mutations

Mesh:

Year:  2018        PMID: 29895694      PMCID: PMC6042135          DOI: 10.1073/pnas.1803155115

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  62 in total

Review 1.  Lessons from the cancer genome.

Authors:  Levi A Garraway; Eric S Lander
Journal:  Cell       Date:  2013-03-28       Impact factor: 41.582

2.  Tug-of-war between driver and passenger mutations in cancer and other adaptive processes.

Authors:  Christopher D McFarland; Leonid A Mirny; Kirill S Korolev
Journal:  Proc Natl Acad Sci U S A       Date:  2014-10-02       Impact factor: 11.205

3.  Only three driver gene mutations are required for the development of lung and colorectal cancers.

Authors:  Cristian Tomasetti; Luigi Marchionni; Martin A Nowak; Giovanni Parmigiani; Bert Vogelstein
Journal:  Proc Natl Acad Sci U S A       Date:  2014-12-22       Impact factor: 11.205

Review 4.  The cancer genome.

Authors:  Michael R Stratton; Peter J Campbell; P Andrew Futreal
Journal:  Nature       Date:  2009-04-09       Impact factor: 49.962

5.  Intratumor heterogeneity and branched evolution revealed by multiregion sequencing.

Authors:  Marco Gerlinger; Andrew J Rowan; Stuart Horswell; James Larkin; David Endesfelder; Eva Gronroos; Pierre Martinez; Nicholas Matthews; Aengus Stewart; Charles Swanton; M Math; Patrick Tarpey; Ignacio Varela; Benjamin Phillimore; Sharmin Begum; Neil Q McDonald; Adam Butler; David Jones; Keiran Raine; Calli Latimer; Claudio R Santos; Mahrokh Nohadani; Aron C Eklund; Bradley Spencer-Dene; Graham Clark; Lisa Pickering; Gordon Stamp; Martin Gore; Zoltan Szallasi; Julian Downward; P Andrew Futreal
Journal:  N Engl J Med       Date:  2012-03-08       Impact factor: 91.245

6.  COSMIC: exploring the world's knowledge of somatic mutations in human cancer.

Authors:  Simon A Forbes; David Beare; Prasad Gunasekaran; Kenric Leung; Nidhi Bindal; Harry Boutselakis; Minjie Ding; Sally Bamford; Charlotte Cole; Sari Ward; Chai Yin Kok; Mingming Jia; Tisham De; Jon W Teague; Michael R Stratton; Ultan McDermott; Peter J Campbell
Journal:  Nucleic Acids Res       Date:  2014-10-29       Impact factor: 16.971

7.  Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden.

Authors:  Zachary R Chalmers; Caitlin F Connelly; David Fabrizio; Laurie Gay; Siraj M Ali; Riley Ennis; Alexa Schrock; Brittany Campbell; Adam Shlien; Juliann Chmielecki; Franklin Huang; Yuting He; James Sun; Uri Tabori; Mark Kennedy; Daniel S Lieber; Steven Roels; Jared White; Geoffrey A Otto; Jeffrey S Ross; Levi Garraway; Vincent A Miller; Phillip J Stephens; Garrett M Frampton
Journal:  Genome Med       Date:  2017-04-19       Impact factor: 11.117

8.  Tissue-specific mutation accumulation in human adult stem cells during life.

Authors:  Francis Blokzijl; Joep de Ligt; Myrthe Jager; Valentina Sasselli; Sophie Roerink; Nobuo Sasaki; Meritxell Huch; Sander Boymans; Ewart Kuijk; Pjotr Prins; Isaac J Nijman; Inigo Martincorena; Michal Mokry; Caroline L Wiegerinck; Sabine Middendorp; Toshiro Sato; Gerald Schwank; Edward E S Nieuwenhuis; Monique M A Verstegen; Luc J W van der Laan; Jeroen de Jonge; Jan N M IJzermans; Robert G Vries; Marc van de Wetering; Michael R Stratton; Hans Clevers; Edwin Cuppen; Ruben van Boxtel
Journal:  Nature       Date:  2016-10-03       Impact factor: 49.962

9.  Mutational landscape and significance across 12 major cancer types.

Authors:  Cyriac Kandoth; Michael D McLellan; Fabio Vandin; Kai Ye; Beifang Niu; Charles Lu; Mingchao Xie; Qunyuan Zhang; Joshua F McMichael; Matthew A Wyczalkowski; Mark D M Leiserson; Christopher A Miller; John S Welch; Matthew J Walter; Michael C Wendl; Timothy J Ley; Richard K Wilson; Benjamin J Raphael; Li Ding
Journal:  Nature       Date:  2013-10-17       Impact factor: 49.962

10.  Whole-exome sequencing and clinical interpretation of formalin-fixed, paraffin-embedded tumor samples to guide precision cancer medicine.

Authors:  Eliezer M Van Allen; Nikhil Wagle; Petar Stojanov; Danielle L Perrin; Kristian Cibulskis; Sara Marlow; Judit Jane-Valbuena; Dennis C Friedrich; Gregory Kryukov; Scott L Carter; Aaron McKenna; Andrey Sivachenko; Mara Rosenberg; Adam Kiezun; Douglas Voet; Michael Lawrence; Lee T Lichtenstein; Jeff G Gentry; Franklin W Huang; Jennifer Fostel; Deborah Farlow; David Barbie; Leena Gandhi; Eric S Lander; Stacy W Gray; Steven Joffe; Pasi Janne; Judy Garber; Laura MacConaill; Neal Lindeman; Barrett Rollins; Philip Kantoff; Sheila A Fisher; Stacey Gabriel; Gad Getz; Levi A Garraway
Journal:  Nat Med       Date:  2014-05-18       Impact factor: 53.440

View more
  31 in total

Review 1.  A systems approach to clinical oncology uses deep phenotyping to deliver personalized care.

Authors:  James T Yurkovich; Qiang Tian; Nathan D Price; Leroy Hood
Journal:  Nat Rev Clin Oncol       Date:  2019-10-16       Impact factor: 66.675

Review 2.  Sex disparities matter in cancer development and therapy.

Authors:  Sue Haupt; Franco Caramia; Sabra L Klein; Joshua B Rubin; Ygal Haupt
Journal:  Nat Rev Cancer       Date:  2021-04-20       Impact factor: 60.716

3.  Tumor somatic mutations also existing as germline polymorphisms may help to identify functional SNPs from genome-wide association studies.

Authors:  Ivan P Gorlov; Xiangjun Xia; Spiridon Tsavachidis; Olga Y Gorlova; Christopher I Amos
Journal:  Carcinogenesis       Date:  2020-10-15       Impact factor: 4.944

Review 4.  Current and Emerging Methods for Ovarian Cancer Screening and Diagnostics: A Comprehensive Review.

Authors:  Juliane M Liberto; Sheng-Yin Chen; Ie-Ming Shih; Tza-Huei Wang; Tian-Li Wang; Thomas R Pisanic
Journal:  Cancers (Basel)       Date:  2022-06-11       Impact factor: 6.575

5.  Cancer Relevance of Human Genes.

Authors:  Tao Qing; Hussein Mohsen; Vincent L Cannataro; Michal Marczyk; Mariya Rozenblit; Julia Foldi; Michael Murray; Jeffrey P Townsend; Yuval Kluger; Mark Gerstein; Lajos Pusztai
Journal:  J Natl Cancer Inst       Date:  2022-07-11       Impact factor: 11.816

Review 6.  Evolutionary classification of CRISPR-Cas systems: a burst of class 2 and derived variants.

Authors:  Kira S Makarova; Yuri I Wolf; Jaime Iranzo; Sergey A Shmakov; Omer S Alkhnbashi; Stan J J Brouns; Emmanuelle Charpentier; David Cheng; Daniel H Haft; Philippe Horvath; Sylvain Moineau; Francisco J M Mojica; David Scott; Shiraz A Shah; Virginijus Siksnys; Michael P Terns; Česlovas Venclovas; Malcolm F White; Alexander F Yakunin; Winston Yan; Feng Zhang; Roger A Garrett; Rolf Backofen; John van der Oost; Rodolphe Barrangou; Eugene V Koonin
Journal:  Nat Rev Microbiol       Date:  2019-12-19       Impact factor: 60.633

7.  Shared Immunogenic Poly-Epitope Frameshift Mutations in Microsatellite Unstable Tumors.

Authors:  Vladimir Roudko; Cansu Cimen Bozkus; Theofano Orfanelli; Christopher B McClain; Caitlin Carr; Timothy O'Donnell; Lauren Chakraborty; Robert Samstein; Kuan-Lin Huang; Stephanie V Blank; Benjamin Greenbaum; Nina Bhardwaj
Journal:  Cell       Date:  2020-11-30       Impact factor: 41.582

8.  Multiomics analysis reveals CT83 is the most specific gene for triple negative breast cancer and its hypomethylation is oncogenic in breast cancer.

Authors:  Chen Chen; Dan Gao; Jinlong Huo; Rui Qu; Youming Guo; Xiaochi Hu; Libo Luo
Journal:  Sci Rep       Date:  2021-06-09       Impact factor: 4.379

Review 9.  Tumor-induced neurogenesis and immune evasion as targets of innovative anti-cancer therapies.

Authors:  Rodolfo Daniel Cervantes-Villagrana; Damaris Albores-García; Alberto Rafael Cervantes-Villagrana; Sara Judit García-Acevez
Journal:  Signal Transduct Target Ther       Date:  2020-06-18

10.  Identification of Genetic Mutations in Cancer: Challenge and Opportunity in the New Era of Targeted Therapy.

Authors:  Jing Jin; Xu Wu; Jianhua Yin; Mingxing Li; Jing Shen; Jing Li; Yueshui Zhao; Qijie Zhao; Jingbo Wu; Qinglian Wen; Chi Hin Cho; Tao Yi; Zhangang Xiao; Liping Qu
Journal:  Front Oncol       Date:  2019-04-16       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.